Kolek planning to go pro
I don't anymore. It was just a comment on the programming and how I feel about it. I'm not watching it every day cursing it.As for DIS, the Disney+ bundling is one of the first times in awhile it feels like Disney is truly taking advantage of and monetizing their gargantuan media presence. Its truly extremely well done and a monster "all ages" spread that puts a shock into Netflix.
CNBC got some hunnies tho
Would strongly encourage all to get into AMRN, ASAP - as in Monday. I put 50% of my portfolio into it back in July and used another 25% to buy the dips the last 5 months for dollar cost average of $18 per share.AMRN's Vascepa will revolutionize the way we treat heart disease, diabetes, strokes, and potentially dementia.Other strong biotech play: IGMSStock I took a flier on and kind of like is WRTC.
AMRN is at ATH, are they dropping some news on Monday or what?
They halted stock from trading Friday at 1:06 EST due to pending announcement of broadened FDA approval for their drug. Released news 5:00EST Friday, resumed trading at 5:30 EST in After Hours...up another $2.66 after hours - but institutional investors were on sidelines. Only 3 million shares changed hands after hours.This company is very likely to get bought out in next 6 months, but also very well prepared to go it alone.They doubled revenue from $200M in 2018 to on track for $410M in 2019, with only and indication to treat patients with triglycerides over 500 (which is crazy high and small market.) What came out Friday lowered that figure to 150, and also was suggested to be indicated for diabetics, and stroke patients.
The Oppenheimer analyst raised his price target to....$8?? That's pretty weird
Isn’t it at $23 now?
Down almost 12% for the week. Pump and dump?
Vascepa is just prescription EPA... ie, fish oil. If you had a tolerance and budget for mass doses (2-4 g of EPA) you could recreate that drug at GNC. While I buy the science and benefit of the treatment, I have some lingering doubts that calling super high dose fish oil a prescription drug is a viable economic model. But, to be honest, I haven't dug too deeply into how they propose to do distribution/pricing, so maybe their play is to try to foist the cost onto he insurance industry?
I bought back in today. I'd be shocked if this isn't trading at $40 within 12 months, if not bought out sooner. Weak retail hands sold the last two days. Some of which have had positions at the $2 level, so can't blame them. However, the institutions want in, now that product is completely de-risked.This will be part of the education process of sales force, and PR staff - as this is common perception. Vascepa is derived from fish oil, but it is purified, 100% EPA (no DHA). Taking OTC Fish Oil will NOT reduce your CV risk, and has actually been shown to have negative risk factors.**Having said all of the above, there of course are no guarantees in investing, yet from my very deep due diligence on this stock/drug, I am quite confident it will be a near and long term winner.**
Wow, I'm very concerned for Benny. Being able to mimic Myron Medcalf's writing so closely implies an oncoming case of dementia.
I bought back in today.
Weak retail hands sold the last two days.
However, the institutions want in, now that product is completely de-risked.
Hold on, "back in"? So after telling up that you had put 75% of your portfolio in this and urging everyone to buy ASAP on Monday morning, you are now claiming that you actually sold? And therefore, despite what you said here, miraculously avoided the (.75*-.1464) = 10.98% loss of your total portfolio value since the close on Friday?Including yourself, from what you said above?From the admittedly limited DD I did, it appears that the new label was narrower than anticipated, and therefore the addressable market and potential revenue smaller than hoped for as well. It appears to be a classic buy the rumor, sell the news situation, particularly if the news is less than what was anticipated and the run up was huge, as this one was.And this is based on what information? Certainly buyers have had ample opportunity to buy in with the more than 14% drop since Friday.Look, I have no opinion on the long-term prospects for this stock. It may very well be long-term winner and you will be right, I haven't done enough DD nor do I understand the addressable market or competitors well enough to warrant an opinion. But pumping the stock, than claiming you actually sold the stock only to buy in lower and coming up with a bunch of rationalizations about why it went down is a recipe for bad investing. I've made a LOT of investing mistakes, and it is a lot better to figure out what went wrong rather than repeat the disasters.
Clarification. I bought more today - haven't sold any since beginning to accumulate back in July. Bought the dip today, just as I have done the past 6 months. Simple dollar cost averaging.
Got it. Sorry I misunderstood.
No worries. I'd have interpreted it the same...worded that poorly in my haste. And, I should point out I very well could be wrong about AMRN. Your points certainly have merit. This is a case where I have done a lot of DD, and feel pretty comfortable and plan to hold long term.
If you are right, and they expand the indications, you'll have a multi-bag winner, which is what we all live for in investing. Good luck!
Interactive Brokers I think